AARTIDRUGS
Aarti Drugs Limited (AARTIDRUGS) Stock Analysis
Aarti Drugs Limited is an Indian pharmaceutical company specializing in API manufacturing and finished formulations. It produces active pharmaceutical ingredients and formulations across therapeutic areas including antibiotics and vitamins. The company serves domestic and international generic pharma customers. It is part of the Aarti group of companies and is listed on Indian exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹396.40
-4.10% 1W | -22.60% 52W
Market Cap
3.6k CR
P/E Ratio
18.9
52W High
₹534
52W Low
₹318.9
Div. Yield
0.5%
Beta
0.3
50 DMA
₹422.4
200 DMA
₹387.3
Profit Margin
7.1%
Inst. Own.
11%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 661 | 642 | 606 | 620 | 555 | 598 | 557 | 677 | 591 | 653 | 602 | 720 | 703 |
| Expenses | 577 | 565 | 536 | 534 | 490 | 531 | 495 | 583 | 516 | 569 | 547 | 624 | 605 |
| Operating Profit | 84 | 76 | 70 | 86 | 65 | 67 | 62 | 93 | 74 | 84 | 55 | 96 | 98 |
| OPM % | 13% | 12% | 12% | 14% | 12% | 11% | 11% | 14% | 13% | 13% | 9% | 13% | 14% |
| Other Income | 1 | 1 | 2 | 1 | 1 | 1 | 12 | 2 | 0 | 0 | 1 | 1 | -1 |
| Interest | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 8 | 9 |
| Depreciation | 13 | 13 | 13 | 14 | 13 | 14 | 14 | 15 | 15 | 16 | 18 | 18 | 18 |
| Profit before tax | 64 | 56 | 52 | 64 | 44 | 46 | 51 | 71 | 51 | 60 | 29 | 70 | 69 |
| Tax % | 24% | 30% | 29% | 26% | 24% | 24% | 27% | 12% | -6% | 25% | -40% | 21% | 28% |
| Net Profit | 48 | 40 | 37 | 47 | 33 | 35 | 37 | 63 | 54 | 45 | 41 | 55 | 50 |
| EPS in Rs | 5.17 | 4.31 | 3.99 | 5.15 | 3.62 | 3.84 | 4.06 | 6.89 | 5.91 | 4.96 | 4.44 | 6.05 | 5.50 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,097 | 1,140 | 1,195 | 1,244 | 1,561 | 1,806 | 2,155 | 2,489 | 2,716 | 2,529 | 2,387 | 2,565 | 2,678 |
| Expenses | 925 | 960 | 1,005 | 1,042 | 1,350 | 1,541 | 1,714 | 2,156 | 2,407 | 2,208 | 2,097 | 2,254 | 2,344 |
| Operating Profit | 172 | 180 | 190 | 202 | 211 | 266 | 440 | 333 | 309 | 321 | 290 | 312 | 333 |
| OPM % | 16% | 16% | 16% | 16% | 14% | 15% | 20% | 13% | 11% | 13% | 12% | 12% | 12% |
| Other Income | 1 | -0 | 4 | 1 | 6 | 6 | 5 | 11 | 2 | 4 | 16 | 2 | 1 |
| Interest | 42 | 48 | 40 | 38 | 44 | 37 | 26 | 24 | 37 | 38 | 39 | 36 | 34 |
| Depreciation | 31 | 37 | 38 | 40 | 43 | 49 | 50 | 50 | 50 | 51 | 56 | 67 | 71 |
| Profit before tax | 100 | 95 | 116 | 125 | 131 | 185 | 369 | 270 | 224 | 236 | 212 | 211 | 229 |
| Tax % | 23% | 28% | 29% | 34% | 32% | 24% | 24% | 24% | 26% | 27% | 21% | 8% | |
| Net Profit | 77 | 69 | 82 | 82 | 90 | 141 | 280 | 205 | 166 | 172 | 168 | 195 | 191 |
| EPS in Rs | 7.97 | 7.09 | 8.57 | 8.73 | 9.52 | 15.17 | 30.09 | 22.14 | 17.96 | 18.65 | 18.42 | 21.36 | 20.95 |
| Dividend Payout % | 41% | 24% | 3% | 3% | 3% | 3% | 8% | 5% | 6% | 5% | 5% | 9% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -2.0% | 4.0% | 8.0% |
| Profit CAGR | 5.0% | -7.0% | 11.0% |
Shareholding Pattern
Promoters55.23%
FIIs2.26%
DIIs9.94%
Public32.58%
Promoters54.72%
FIIs2.68%
DIIs9.90%
Public32.70%
Promoters55.03%
FIIs2.15%
DIIs10.12%
Public32.71%
Promoters55.03%
FIIs1.57%
DIIs10.22%
Public33.19%
Promoters54.43%
FIIs1.52%
DIIs10.29%
Public33.76%
Promoters59.57%
FIIs1.94%
DIIs4.09%
Public34.39%
Promoters57.13%
FIIs2.56%
DIIs5.99%
Public34.30%
Promoters55.48%
FIIs2.25%
DIIs9.70%
Public32.57%
Promoters55.03%
FIIs1.57%
DIIs10.22%
Public33.19%
Promoters54.43%
FIIs1.52%
DIIs10.29%
Public33.76%
AARTIDRUGS
Holdings Analysis
Key strengths & risk signals
53
Overall
45
Fundamental
62
Technical
Risks (4)
LOW MARGIN! 7.1% profit margin - thin profits.
POOR YEAR! Stock declined 22.6% in the last year.
RECOVERY MODE! Current price (396.4) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.1% (1 week), 6.6% (1 month), 6.1% (3 months).
Strengths (4)
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
BULLISH TREND! 50-day average (422.4) is above 200-day average (387.3) - positive signal.
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 207,046 vs down days: 153,536. Ratio: 1.35x
Fundamental & Technical Analysis
53Overall
45Fundamental
62Technical
Fundamental Breakdown
Growth Quality
10/30
Revenue CAGR: -2.3% (DECLINING, 2/15). Profit CAGR: 5.4% (MODERATE, 8/15).
Profit Margin
3/10
LOW MARGIN! 7.1% profit margin - thin profits.
PEG Valuation
3/10
OVERVALUED! PEG of 3.50 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.5% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 34.63% public ownership - moderate retail influence.
Stability Index
6/10
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (422.4) is above 200-day average (387.3) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (396.4) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
1/10
POOR YEAR! Stock declined 22.6% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 207,046 vs down days: 153,536. Ratio: 1.35x
RSI
4/5
APPROACHING OVERSOLD! RSI at 34.9 - watch for reversal.
52W Range
2/5
LOWER HALF! Trading at 36.0% of 52W range - weakness visible.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.1% (1 week), 6.6% (1 month), 6.1% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
AARTIDRUGS
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-07 | Concall PDF | |
| Q4FY262026-05-23 | Concall PDF | |
| Q3FY262026-02-10 | Concall PDF | |
| Q2FY262025-11-14 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AARTIDRUGS | ₹396.40 | 18.9 | 7.1% | -2.3% | 5.4% | -22.6% | 53 | BREAKDOWN | -6.9% | -9.1% | +19.0% | -2.4% |
| UNICHEMLAB | ₹510.60 | 11.8 | 13.2% | 18.4% | – | +10.7% | 63 | BREAKDOWN | -495.2% | +280.7% | +20.1% | +10.0% |
| SOLARA | ₹696.70 | – | -0.1% | -1.2% | – | +9.6% | 53 | BREAKDOWN | +55.2% | +69.8% | +19.5% | -1.5% |
| INDSWFTLAB | ₹359.20 | 53.7 | 8.5% | -19.7% | -3.2% | +253.4% | 56 | BREAKDOWN | +180.7% | +63.6% | +21.0% | +12.8% |
| GUFICBIO | ₹404.50 | 56.4 | 7.5% | 6.1% | -6.9% | +16.2% | 55 | BREAKDOWN | +70.2% | +1.8% | +16.6% | +3.6% |
| HIKAL | ₹215.60 | – | -1.9% | -5.4% | – | -9.8% | 53 | BREAKDOWN | -67.0% | -151.4% | +7.7% | -22.7% |
| ORCHPHARMA | ₹911.20 | 566 | 3.5% | 22.3% | -40.1% | +28.0% | 66 | BREAKDOWN | -156.1% | -86.6% | +15.6% | +28.0% |
| NOVARTIND | ₹1,897.60 | 47.9 | 26.4% | -1.4% | -3.4% | +195.8% | 65 | CONSOLIDATING DOWN | +16.7% | +27.8% | +18.5% | +14.6% |
Data from TradeAlone · Updated daily
